Special attention has been given to CDK2 subtype as a potential target for the management and treatment of different tumours based on its key role in many cellular processes upon binding to its cyclin A or E partners; such that its complex with cyclin E regulates S phase entry and progression, whereas its binding with cyclin A warrants continuous DNA replication as well as G2/M phase transition20,.21 This evidence concerns the gene CCNA2 and neoplasm.